Skip to main content
SpringerLink
Log in

Bronchospasmolytika und Antiasthmatika

  • Chapter
Arzneiverordnungs-Report 2017

  • 2104 Accesses

Zusammenfassung

Bronchospasmolytika werden zur Behandlung des Asthma bronchiale und der chronisch-obstruktiven Lungenkrankheit (COPD) eingesetzt. Bei beiden Erkrankungen ist es das Ziel, die Bronchialobstruktion, die beim Asthma besser reversibel ist als bei der COPD, zu reduzieren. Im Spätstadium der COPD mit Ateminsuffizienz, Emphysem und Cor pulmonale sollen die Symptome so weit wie möglich gebessert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alagha K, Palot A, Sofalvi T, Pahus L, Goultra M, Tummino C, Martinez S, Charpin D, Bourdin A, Chanez P (2014): Long-acting muscarinic antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis 5: 85–98

    Google Scholar 

  • Barnes PJ (2008): Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8: 183–192

    Google Scholar 

  • Barnes P (2012): Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol 129: 48–59

    Google Scholar 

  • Barnes PJ (2015): Therapeutic approaches to asthma–chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol 136:531-545

    Google Scholar 

  • Befekadu E, Onofrei C, Collice GL (2014): Tiotropium in asthma: a systematic review. J Asthma Allergy 7: 11–21

    Google Scholar 

  • Brand PL (2011): Inhaled corticosteroids should be the first line of treatment for children with asthma. Paediatr Respir Rev 12: 245–249

    Google Scholar 

  • Buhl R (2008): Atemwegserkrankungen: Moderne Therapiekonzepte für adäquate Behandlungsstrategien. J Pharmakol Ther 17: 95

    Google Scholar 

  • Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (1998): Arzneimittel mit problematischer Bioverfügbarkeit. 9. Bekanntmachung gemäß §26, Abs. 3 AMG vom 19.1.1998

    Google Scholar 

  • Bundesministerium für Gesundheit (2014): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) und Anlage IX – Festbetragsgruppenbildung Beta2-Sympathomimetika, inhalativ oral, Gruppe 1, in Stufe 2 nach § 35a Absatz 3 in Verbindung mit Absatz 4 Satz 1 SGB V vom 17. Juli 2014, veröffentlicht am Montag, 11. August 2014 BAnz AT 11.08.2014 B3

    Google Scholar 

  • Bundesministerium für Gesundheit (2016): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Aclidiniumbromid vom 7.4.2016 veröffentlicht am 7. April 2016, BAnz AT 03.05.2016 B3

    Google Scholar 

  • Cates CJ, Cates MJ (2008): Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev, July 16: CD006363

    Google Scholar 

  • Chauhan BF, Chartrand C, Ducharme FM (2013a): Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. Issue 2, Art. No. CD009611

    Google Scholar 

  • Chauhan BF, Ben Salah R, Ducharme FM (2013b): Addition of anti-leukotriene agents to inhaled cortocosteroids in children with persisten asthma. Cochrane Database Syst Rev doi: 10.1002/14651858.CD009585.pub2

  • Cingi C, Mulik NB, Ipci K, Sahin E (2015): Antileukotrienes in upper airway inflammatory disease. Curr Allergy Asthma Rep 15:64. Doi: 10.1007/s11882-015-0564-7

  • EMA Press Release (2010): Asthma treatment (long and short-acting Beta agoniststs and anticholinergics): risk of myocardial ischaemia and long-term safety, especially in children. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/07/WC500094267.pdf

  • Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups (2009): Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374: 695–703

    Google Scholar 

  • FDA Press Release (2010): FDA announces new safety controls for long-acting beta agonists, medications used to treat asthma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200931.htm

  • FDA Press Release (2011): FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs). Internet: http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm. Update 8.1.2016

  • Fuhlbrigge AL, Kelly HW (2014): Inhaled corticosteroids in children: effects on bone mineral density and growth. Lancet Respir Med 2: 487-496

    Google Scholar 

  • Gibb A, Yang LPH (2013): Oldaterol: first global approval. Drugs 73:1842–1846

    Google Scholar 

  • Gibson PG, McDonald VM (2015): Asthma-COPD overlap 2015: now were are six. Thorax 70: 683–691

    Google Scholar 

  • Gillissen A, Berdel D, Buhl R et al (2007): β2-Sympathomimetika: Gefahren in der Asthmatherapie? Lehren aus der SMART1-Studie. Dtsch Med Wochenschr 132: 33–39

    Google Scholar 

  • Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from: http://www.goldcopd.org

  • Haasler I, Buhl R, Taube C (2011): Asthma bronchiale: neue Erkenntnisse und Entwicklungen. Dtsch Med Wochenschr 136: 198–200

    Google Scholar 

  • Hines KL, Peebles RS (2017): Management of the asthma-COPD overlap syndrome (ACOS): a review of the evidence. Curr Allergy Asthma Rep 17:doi: 10.1007/s11882-017-0683-4

  • Hizawa N (2016): Clinical approaches towards asthma and chronic obstructive pulmonary disease based on the heterogeneity of disease pathogenesis. Clin Experimental Allergy 46: 679–687

    Google Scholar 

  • Kirsch F, Teuner CM, Menn P, Leidl R (2013): Krankheitskosten für Asthma und COPD bei Erwachsenen in der Bundesrepublik Deutschland. Gesundheitswesen 75: 413–423

    Google Scholar 

  • Kuehn BM (2009): FDA panel: ban 2 popular asthma drugs. JAMA 301: 365–366

    Google Scholar 

  • Küpper T, Goebbels K, Kennes LN, Netzer NC (2012): Cromoglycate, reproterol, or both--what‘s best for exercise-induced asthma? Sleep Breath 16: 1229–1235

    Google Scholar 

  • Lange P, Halpin DM, O’Donnell DE, MacNee W (2016): Diagnosis assessment, and phenotyping of COPD: beyond FEV1. Int J COPD 11: 3–12

    Google Scholar 

  • Lemmer B (1990): Chronopharmakologische Aspekte der Theophyllintherapie. In: Blume H (Hrsg.): Bioäquivalenz retardierter Theophyllin-Fertigarzneimittel. Govi, Frankfurt, S. 75–82

    Google Scholar 

  • Levenson M (2008): Long-Acting Beta-Agonists and Adverse Asthma Events Meta-Analysis. Statistical Briefing Package for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee on December 10–11, 2008. Internet: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf

  • McNicholas WT (2017): COPD-OSA overlap syndrome: evolving evidence regarding epidemioloygy, clinical consequence, and management. Chest: doi:10.10167J-CHSET 2017.04.160

    Google Scholar 

  • Meyer N, Nuss SJ, Rothe T, Siebenhüner A, Akdis CA, Menz G (2014): Differential serum protein markers and the clinical severity of asthma. J Asthma Allergy 7: 67–75

    Google Scholar 

  • National Institutes of Health, National Heart Lung and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. NIH Publication No 07-4051 2007, http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf

  • Nationale Versorgungsleitlinie Asthma, Version 5 (2013). Internet: http://www.versorgungsleitlinien.de/themen/asthma/pdf/nvl-asthma-2aufl.-lang-5.pdf

  • Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group (2006): The salmeterol multicenter asthma research trial: a comparison of unusual pharmacotherapy for asthma or usual pharmacology plus salmeterol. Chest 129: 15–26

    Google Scholar 

  • Ngkelo A, Adcock IM (2013): New Treatment for COPD. Current Opinion Pharmacology. 13: 1–8

    Google Scholar 

  • Nguyen M-H (2015): Olodaterol – Lang wirksamer Beta-2-Adrenozeptor-Agonist zur Dauertherapie bei chronisch obstruktiver Lungenerkrankung (COPD). Arzneimitteltherapie 33: 417-419

    Google Scholar 

  • Normansell R, Walker S, Milan SJ, Walters E, Nair P (2014): Omazilumab for chronoc asthma in adults and children. Coch rane Collaboration DOI: 10.1002/14651858.CD003559.pub4

  • Oba Y, Lone NA (2013): Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 7: 13–24

    Google Scholar 

  • O‘Reilly DA, Awale A, Cartledge P (2015): Question 2: Blast from the past: is oral salbutamol useful in resource-poor settings? Arch Dis Child 100: 806–809

    Google Scholar 

  • Patel M, Pilcher JJ, Pritchard A, Perrin K, Travers J, Shaw D, Holt S, Harwood M, Black P, Weatherhall M, Beasley R, for the SMART Study Group (2013): Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 1: 32–42

    Google Scholar 

  • Pedersen S (2006): Clinical safty of inhaled corticosteroids for asthma in children – an update of long-term trials. Drug Safety 29: 599–612

    Google Scholar 

  • Rank MA, Hagan JB, Park MA, Podjasek JC, Samant SA, Volcheck GW, Erwin PJ, West CP (2013): The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 131: 724–729

    Google Scholar 

  • Rennard SI, Drummond MB (2015): Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet 385:1778–1788

    Google Scholar 

  • Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA (2009): Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review with meta-analysis. Respir Med 103: 1421–1429

    Google Scholar 

  • Schmidt H (1994): Retardtheophyllin ist nicht gleich Retardtheophyllin. Atemwegs-Lungenkr 20: 223–231

    Google Scholar 

  • Singh S, Loke YK, Furberg CD (2008): Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300: 1439–1450

    Google Scholar 

  • Smolensky M, Lemmer B, Reinberg A (2007): The chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Del Rev 59: 852–882

    Google Scholar 

  • Tashkin DP, Celli B, Senn S, Burkhadt D, Kesten S, Menjoge S, Decramer M (2008): A 4-year trial of tiotropium in chronic pulmonary disease. N Engl J Med 359: 1543–1554

    Google Scholar 

  • Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S (2012): Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD 9: 289–296

    Google Scholar 

  • Watts KL, Chavasse RJ (2012): Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev. May, 16; 5: CD006100

    Google Scholar 

  • Woodruff PG, Augusti A, Roche N, Singh D, Martinez FJ (2015): Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 385: 1789–1798

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fakultät für Klinische Medizin Mannheim der Universität Heidelber, Institut für Pharmakologie und Toxikologie, Maybachstraße 14–16, 68169, Mannheim, Deutschland

    Björn Lemmer

Authors
  1. Björn Lemmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn Lemmer .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Germany

About this chapter

Cite this chapter

Lemmer, B. (2017). Bronchospasmolytika und Antiasthmatika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54630-7_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54629-1

  • Online ISBN: 978-3-662-54630-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation